Recent studies into retatrutide, a dual agonist for GLP-1 and GIP receptors, are demonstrating encouraging outcomes in addressing obesity and type non-insulin-dependent condition. Preclinical data suggest a novel https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/